KOD Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 7.47%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -21.86%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 7.9%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 11.83x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -15814.98%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Cytokinetics, Inc.'s return on equity of --.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -21.86%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $85.44 which suggests that it could grow by 33.13%. Given that Cytokinetics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Cytokinetics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Cytokinetics, Inc. quarterly revenues of $1.9M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 87.58x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -255.85%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -21.86%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that NovaBay Pharmaceuticals, Inc. has more downside risk than Kodiak Sciences, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Processa Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of --. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Processa Pharmaceuticals, Inc.'s return on equity of -309.65%.

Kodiak Sciences, Inc. has a consensus price target of $24.29, signalling downside risk potential of -21.86%. On the other hand Processa Pharmaceuticals, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 612.25%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.684, which suggesting that the stock is 168.415% more volatile than S&P 500. In comparison Processa Pharmaceuticals, Inc. has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.404%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Processa Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Processa Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Processa Pharmaceuticals, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Processa Pharmaceuticals, Inc.'s net income of -$3.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Processa Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus -- for Processa Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.